Who
Muna Bhanji
Director
Company insider
Files Form 4 as: Director, Veracyte; Director, Ardelyx; Director, Intellia Therapeutics; Director, Cytokinetics.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $982K
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 17 Feb 2021
- Last trade
- 19 Oct 2026
- Last filed
- 20 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 20 Oct 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $81K1,864 at $43.70 | filing |
| 1 Sep 2026filed 3 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $80K1,864 at $42.97 | filing |
| 1 Sep 2026filed 3 Sep 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Sold | $80K1,864 at $42.97 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,715 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —26,455 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —5,272 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK Cytokineticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,301 at $0.00 | filing |
| 27 May 2026filed 27 May 2026 | CYTK CytokineticsBiotechnology | SEC FORM 4 Code A | —2,851 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | VCYT VeracyteDiagnostics & Labs | SEC FORM 4 Code A | —9,321 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX Ardelyxoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,059 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | ARDX ArdelyxBiotechnology | SEC FORM 4 Code A | —41,551 at $0.00 | filing |
News
Veracyte's Decipher Can Help Men Detect Prostate CancerVCYT · finanzen.ch · 23 Oct 2026Phase III Trial Shows Veracyte's Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerVCYT · manilatimes.net · 23 Oct 2026
0 headlines in the last 90 days name Muna Bhanji; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.